$ALKS
Alkermes plc.

2023 Q4 Form 10-Q Financial Statement

#000095017023055178 Filed on October 25, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $377.5M $380.9M
YoY Change 23.89% 50.95%
Cost Of Revenue $70.13M $61.51M
YoY Change 29.95% 21.5%
Gross Profit $307.3M $319.4M
YoY Change 22.59% 58.34%
Gross Profit Margin 81.42% 83.85%
Selling, General & Admin $169.8M $169.4M
YoY Change 7.77% 10.91%
% of Gross Profit 55.24% 53.05%
Research & Development $73.93M $97.14M
YoY Change -27.08% -3.28%
% of Gross Profit 24.06% 30.41%
Depreciation & Amortization $8.996M $18.70M
YoY Change -54.28% -4.58%
% of Gross Profit 2.93% 5.85%
Operating Expenses $252.7M $266.6M
YoY Change -6.85% 5.28%
Operating Profit $54.63M $43.85M
YoY Change -365.43% -172.31%
Interest Expense $3.695M $6.006M
YoY Change -535.73% 69.09%
% of Operating Profit 6.76% 13.7%
Other Income/Expense, Net -$10.00K $3.513M
YoY Change -96.12% -152.22%
Pretax Income $58.32M $47.36M
YoY Change -368.89% -170.3%
Income Tax -$102.2M -$400.0K
% Of Pretax Income -175.31% -0.84%
Net Earnings $112.8M $47.76M
YoY Change -499.16% -174.65%
Net Earnings / Revenue 29.88% 12.54%
Basic Earnings Per Share $0.29
Diluted Earnings Per Share $0.66 $0.28
COMMON SHARES
Basic Shares Outstanding 166.9M 166.6M
Diluted Shares Outstanding 171.9M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $813.4M $889.2M
YoY Change 33.68% 53.25%
Cash & Equivalents $813.4M $647.7M
Short-Term Investments $316.0M $241.4M
Other Short-Term Assets $98.17M $43.00M
YoY Change 125.53% 7.39%
Inventory $186.4M $192.2M
Prepaid Expenses
Receivables $333.2M $340.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.431B $1.465B
YoY Change 26.61% 39.0%
LONG-TERM ASSETS
Property, Plant & Equipment $226.9M $327.5M
YoY Change -30.25% 0.36%
Goodwill $83.03M $92.87M
YoY Change -10.6% 0.0%
Intangibles
YoY Change
Long-Term Investments $39.89M $106.4M
YoY Change -69.69% -36.26%
Other Assets $393.1M $11.29M
YoY Change 2575.99% 2.83%
Total Long-Term Assets $705.1M $814.5M
YoY Change -15.42% -8.29%
TOTAL ASSETS
Total Short-Term Assets $1.431B $1.465B
Total Long-Term Assets $705.1M $814.5M
Total Assets $2.136B $2.279B
YoY Change 8.77% 17.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $65.65M $87.04M
YoY Change 99.89% 162.16%
Accrued Expenses $444.3M $409.8M
YoY Change -2.37% -4.56%
Deferred Revenue $2.730M $3.319M
YoY Change -59.95% -16.65%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.000M $3.000M
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $515.7M $503.1M
YoY Change 3.6% 7.15%
LONG-TERM LIABILITIES
Long-Term Debt $287.7M $288.4M
YoY Change -0.88% -0.87%
Other Long-Term Liabilities $130.1M $53.62M
YoY Change 207.02% 25.13%
Total Long-Term Liabilities $417.9M $342.0M
YoY Change 25.61% 2.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $515.7M $503.1M
Total Long-Term Liabilities $417.9M $342.0M
Total Liabilities $933.5M $923.6M
YoY Change 1.45% 2.74%
SHAREHOLDERS EQUITY
Retained Earnings -$1.344B -$1.456B
YoY Change -20.94% -12.85%
Common Stock $2.739B $3.005B
YoY Change -6.04% 4.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.203B $1.356B
YoY Change
Total Liabilities & Shareholders Equity $2.136B $2.279B
YoY Change 8.77% 17.37%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $112.8M $47.76M
YoY Change -499.16% -174.65%
Depreciation, Depletion And Amortization $8.996M $18.70M
YoY Change -54.28% -4.58%
Cash From Operating Activities $107.3M $99.70M
YoY Change 10143.84% 15852.0%
INVESTING ACTIVITIES
Capital Expenditures $17.05M $14.40M
YoY Change 70.0% -237.48%
Acquisitions
YoY Change
Other Investing Activities -$3.995M -$104.9M
YoY Change -110.58% -641.5%
Cash From Investing Activities -$20.94M -$119.4M
YoY Change -175.5% -1441.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -276.5M 1.600M
YoY Change 101934.69% -854.72%
NET CHANGE
Cash From Operating Activities 107.3M 99.70M
Cash From Investing Activities -20.94M -119.4M
Cash From Financing Activities -276.5M 1.600M
Net Change In Cash -190.2M -18.10M
YoY Change -767.01% -294.39%
FREE CASH FLOW
Cash From Operating Activities $107.3M $99.70M
Capital Expenditures $17.05M $14.40M
Free Cash Flow $90.20M $85.30M
YoY Change -1104.4% 668.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
647711000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292473000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
337697000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
287967000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.42
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
241439000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
315992000
CY2023Q3 us-gaap Inventory Net
InventoryNet
192186000
CY2022Q4 us-gaap Inventory Net
InventoryNet
181418000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001520262
dei Entity Registrant Name
EntityRegistrantName
Alkermes plc.
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35299
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1007018
dei Entity Address Address Line1
EntityAddressAddressLine1
Connaught House
dei Entity Address Address Line2
EntityAddressAddressLine2
1 Burlington Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 4
dei Entity Address Country
EntityAddressCountry
IE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D04 C5Y6
dei City Area Code
CityAreaCode
353
dei Local Phone Number
LocalPhoneNumber
1-772-8000
dei Security12b Title
Security12bTitle
Ordinary shares, $0.01 par value
dei Trading Symbol
TradingSymbol
ALKS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
166881286
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
2766000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8929000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42982000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43527000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1464781000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1130306000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
327517000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
325361000
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
106431000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
131610000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
103170000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115855000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10987000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
37680000
CY2023Q3 us-gaap Goodwill
Goodwill
92873000
CY2022Q4 us-gaap Goodwill
Goodwill
92873000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
162184000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
115602000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11288000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14691000
CY2023Q3 us-gaap Assets
Assets
2279231000
CY2022Q4 us-gaap Assets
Assets
1963978000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
243263000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220089000
CY2023Q3 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
238467000
CY2022Q4 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
252115000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15058000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15722000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3319000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6816000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
503107000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
497742000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
288366000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
290270000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78552000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89829000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
53623000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42384000
CY2023Q3 us-gaap Liabilities
Liabilities
923648000
CY2022Q4 us-gaap Liabilities
Liabilities
920225000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
172218651
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168951193
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166714095
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164377009
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1722000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1690000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5504556
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4574184
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
186942000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
160862000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3003184000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2913099000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6074000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10889000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1456307000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1699285000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1355583000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1043753000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2279231000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1963978000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
380938000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
252357000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1285930000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
807121000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
61509000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
50625000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
182944000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
164144000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97140000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100430000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
291565000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
289256000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
169446000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152777000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
549181000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
448206000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8995000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
9166000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
26693000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27198000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
337090000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
312998000
us-gaap Costs And Expenses
CostsAndExpenses
1050383000
us-gaap Costs And Expenses
CostsAndExpenses
928804000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
43848000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-60641000
us-gaap Operating Income Loss
OperatingIncomeLoss
235547000
us-gaap Operating Income Loss
OperatingIncomeLoss
-121683000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9370000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2239000
us-gaap Investment Income Interest
InvestmentIncomeInterest
21105000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3708000
CY2023Q3 us-gaap Interest Expense
InterestExpense
6006000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3552000
us-gaap Interest Expense
InterestExpense
16978000
us-gaap Interest Expense
InterestExpense
8271000
CY2022Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-3553000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-21750000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
149000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1861000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-415000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2380000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3513000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6727000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3712000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23933000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
47361000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67368000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
239259000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145616000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-397000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3394000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3719000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-15603000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
47758000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-63974000
us-gaap Net Income Loss
NetIncomeLoss
242978000
us-gaap Net Income Loss
NetIncomeLoss
-130013000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166607000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164282000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165996000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163541000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171903000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164282000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
170981000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
163541000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
47758000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-63974000
us-gaap Net Income Loss
NetIncomeLoss
242978000
us-gaap Net Income Loss
NetIncomeLoss
-130013000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
216000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-188000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
803000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1242000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1363000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2349000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4815000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9114000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
49121000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66323000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
247793000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-139127000
us-gaap Profit Loss
ProfitLoss
242978000
us-gaap Profit Loss
ProfitLoss
-130013000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56386000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58185000
us-gaap Share Based Compensation
ShareBasedCompensation
75062000
us-gaap Share Based Compensation
ShareBasedCompensation
67771000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-47385000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-54073000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-21750000
us-gaap Other Noncash Expense
OtherNoncashExpense
1394000
us-gaap Other Noncash Expense
OtherNoncashExpense
3746000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
49730000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-56045000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-6163000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-3258000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9866000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15646000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-3947000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1872000
alks Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-12685000
alks Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-12470000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
20958000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6386000
alks Increase Decrease In Accrued Sales Discount Allowances And Reserves
IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves
-13649000
alks Increase Decrease In Accrued Sales Discount Allowances And Reserves
IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves
-1576000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5724000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9191000
alks Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-12569000
alks Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-13411000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
13466000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
12424000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
294116000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
19997000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31018000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28227000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
alks Proceeds From Contingent Consideration
ProceedsFromContingentConsideration
1273000
alks Return Of Investments
ReturnOfInvestments
485000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
186593000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
256806000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
291944000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
190994000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
74339000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92281000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
15113000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18850000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
26080000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17903000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2250000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13217000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1303000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
355238000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-73587000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
292473000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
337544000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
647711000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263957000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
4209000
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
2690000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1043753000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2874000
CY2023Q1 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-24744000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22778000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
488000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2760000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1005576000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9126000
CY2023Q2 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-540000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28518000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
99000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
692000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
237065000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1280437000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3113000
CY2023Q3 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-796000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23708000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
216000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1363000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
47758000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1355583000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1112584000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1795000
CY2022Q1 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-17069000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18494000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1382000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4511000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1075390000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16197000
CY2022Q2 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-514000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23641000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
326000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2254000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30136000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1082324000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
858000
CY2022Q3 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-320000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26315000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-188000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2349000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-63974000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1042854000
CY2022Q4 alks Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
2467000
us-gaap Nature Of Operations
NatureOfOperations
<p id="notes_to_financial_statements" style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. THE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span id="n1_company"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMPANY</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alkermes plc is a fully-integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Alkermes has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, the Company has a research and development (“R&amp;D”) center in Waltham, Massachusetts; an R&amp;D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, the Company announced its intent, as approved by its board of directors, to explore the separation of its oncology business. Following a review of strategic alternatives for the oncology business, the Company is planning a separation of the oncology business into an independent, publicly-traded company (referred to herein as “Mural Oncology”). Following the planned separation, the Company would focus on driving growth of its proprietary commercial products: LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. The Company also expects to retain manufacturing and royalty revenues, including those related to its licensed products and third-party products using its proprietary technologies under license. Mural Oncology would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the Company’s portfolio of novel, preclinical engineered cytokines. The separation, if consummated, is expected to be completed in November 2023 and is subject to customary closing conditions, including final approval by the Company’s board of directors and receipt of a private letter ruling from the U.S. Internal Revenue Service (the “IRS”) and/or a tax opinion from the Company’s tax advisor. Subsequent to the planned separation, the historical results of the oncology business will be reflected as discontinued operations in the Company’s consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including, but not limited to, those related to revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different conditions or using different assumptions.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months Accumulated Loss Non Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12MonthsAccumulatedLossNonCurrent
2291000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
129790000
CY2022Q4 alks Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
136368000
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8929000
us-gaap Contract With Customer Asset Purchase
ContractWithCustomerAssetPurchase
12881000
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
19044000
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2766000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10701000
alks Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
-931000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-4794000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4976000
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
243623000
CY2023Q3 alks Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
19000
CY2023Q3 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossCurrent
51000
CY2023Q3 alks Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossCurrent
2152000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
241439000
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
106158000
CY2023Q3 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Noncurrent
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossNoncurrent
203000
CY2023Q3 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months Accumulated Loss Non Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12MonthsAccumulatedLossNonCurrent
1344000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
104611000
CY2023Q3 alks Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
107978000
CY2023Q3 alks Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
203000
CY2023Q3 alks Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
1344000
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
106431000
CY2023Q3 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
351601000
CY2023Q3 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
19000
CY2023Q3 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
254000
CY2023Q3 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
3496000
CY2023Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
347870000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
320583000
CY2022Q4 alks Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
16000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossCurrent
718000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossCurrent
3889000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
315992000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
134548000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Noncurrent
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossNoncurrent
2467000
CY2022Q4 alks Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
2291000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
131610000
CY2022Q4 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
456951000
CY2022Q4 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
16000
CY2022Q4 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
3185000
CY2022Q4 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
6180000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
447602000
alks Number Of Unrealized Investment Securities
NumberOfUnrealizedInvestmentSecurities
179
alks Number Of Investment Securities
NumberOfInvestmentSecurities
219
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
280300000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
291944000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
190994000
alks Marketable Securities Realized Loss
MarketableSecuritiesRealizedLoss
529000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
214322000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
212122000
CY2023Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
1820000
CY2023Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
1820000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
135459000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
133928000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
349781000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
346050000
CY2023Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
1820000
CY2023Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
1820000
alks Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level One To Level Two
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo
0
alks Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level Two To Level One
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
68315000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
61064000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
73457000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
76228000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
50414000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
44126000
CY2023Q3 us-gaap Inventory Net
InventoryNet
192186000
CY2022Q4 us-gaap Inventory Net
InventoryNet
181418000
CY2023Q3 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
33700000
CY2022Q4 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
30900000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
790213000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
759019000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
462696000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
433658000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
327517000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
325361000
CY2023Q3 us-gaap Goodwill Gross
GoodwillGross
92873000
CY2023Q3 us-gaap Goodwill
Goodwill
92873000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
583750000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
572763000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10987000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
35000000.0
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000.0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4103000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16601000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16848000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12760000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9505000
CY2023Q3 alks Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
69474000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
129291000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
35681000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
93610000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y1M6D
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
4100000
us-gaap Operating Lease Payments
OperatingLeasePayments
12600000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
4500000
us-gaap Operating Lease Payments
OperatingLeasePayments
13400000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
12700000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
4100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
12500000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
87036000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32843000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
67773000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
79085000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88454000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
108161000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
243263000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220089000
CY2023Q3 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
238467000
CY2022Q4 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
252115000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23915000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26051000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75062000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67771000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3200000
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3300000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
47758000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-63974000
us-gaap Net Income Loss
NetIncomeLoss
242978000
us-gaap Net Income Loss
NetIncomeLoss
-130013000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166607000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164282000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165996000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163541000
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
5296000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4985000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171903000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164282000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
170981000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
163541000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13346000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17953000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14811000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18243000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3700000
alks Restructuring And Related Activities Initiation Month And Year
RestructuringAndRelatedActivitiesInitiationMonthAndYear
2023-07
CY2023Q3 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
60
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
6000000
us-gaap Restructuring Charges
RestructuringCharges
6000000
us-gaap Restructuring Charges
RestructuringCharges
5969000
alks Payments For Restructuring Severance
PaymentsForRestructuringSeverance
2098000
alks Payments For Restructuring Benefits
PaymentsForRestructuringBenefits
319000
alks Payments For Restructuring Outplacement Services
PaymentsForRestructuringOutplacementServices
178000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
3374000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
66000000
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-055178-index-headers.html Edgar Link pending
0000950170-23-055178-index.html Edgar Link pending
0000950170-23-055178.txt Edgar Link pending
0000950170-23-055178-xbrl.zip Edgar Link pending
alks-20230930.htm Edgar Link pending
alks-20230930.xsd Edgar Link pending
alks-ex10_1.htm Edgar Link pending
alks-ex10_2.htm Edgar Link pending
alks-ex10_3.htm Edgar Link pending
alks-ex31_1.htm Edgar Link pending
alks-ex31_2.htm Edgar Link pending
alks-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img76599647_0.jpg Edgar Link pending
img76599647_1.jpg Edgar Link pending
img76599647_2.jpg Edgar Link pending
img76599647_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
alks-20230930_lab.xml Edgar Link unprocessable
alks-20230930_cal.xml Edgar Link unprocessable
alks-20230930_def.xml Edgar Link unprocessable
alks-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alks-20230930_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending